Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Merck Sharp & Dohme LLC9 enrolled

Overview

The primary purpose of this clinical study is to determine the recommended clinical doses of vorinostat (MK-0683) and bortezomib administered in combination to participants with relapsed and/or refractory multiple myeloma (MM). It was hypothesized that administration of vorinostat in combination with bortezomib is sufficiently safe and tolerated well enough to permit further study in participants with relapsed and/or refractory MM. Study results are based on data collected up to the data cut-off date of 20-March-2011.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Multiple Myeloma

Interventions

VorinostatDRUG

Vorinostat (MK-0683) three or four 100 mg capsules taken by mouth with food.

BortezomibDRUG

Bortezomib (1.0 or 1.3 mg/m\^2) intravenous infusion.

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * is ≥20 years of age. * has an established diagnosis of MM based on the myeloma diagnostic criteria * has received at least 1 but not more than 3 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen * has adequate organ function Exclusion Criteria: * has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation during the study * has known hypersensitivity to any components of vorinostat or bortezomib * has active hepatitis B or C, plasma cell leukemia, or is human immunodeficiency virus (HIV) positive * has had prior treatment with vorinostat or histone deacetylase (HDAC) inhibitors

Outcomes

Primary Outcomes

Number of Participants With Dose-Limiting Toxicity (DLT) During Cycle 1

The number of participants with ≥1 DLT during Cycle 1 is reported. A DLT is defined as an event considered by the investigator to be related to study treatment, and either: 1) a Grade 3 or 4 non-hematologic event (except for manageable toxicity by supportive care or non-prohibited therapies, or a transient increase in alanine aminotransferase \[ALT\]/aspartate aminotransferase \[AST\]); or 2) a Grade 4 hematologic toxicity except neutropenia or hemoglobin decreased (neutropenia was a DLT if it was Grade 3-4 with fever ≥38.5°C; Grade 3-4 with an infection requiring antibiotic/antifungal therapy; or Grade 4 and lasting ≥5 days).

Time frame: Up to 21 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.